
Hygon Mutavhatsindi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/768382/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, 2020, 10, 8629.	3.3	90
2	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Science Translational Medicine, 2022, 14, .	12.4	77
3	Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals. Journal of Infection, 2019, 79, 228-235.	3.3	24
4	Potential of Host Serum Protein Biomarkers in the Diagnosis of Tuberculous Meningitis in Children. Frontiers in Pediatrics, 2019, 7, 376.	1.9	24
5	Application of Cerebrospinal Fluid Host Protein Biosignatures in the Diagnosis of Tuberculous Meningitis in Children from a High Burden Setting. Mediators of Inflammation, 2019, 2019, 1-11.	3.0	24
6	Validation and Optimization of Host Immunological Bio-Signatures for a Point-of-Care Test for TB Disease. Frontiers in Immunology, 2021, 12, 607827.	4.8	22
7	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity Science Translational Medicine, 2021, , eabj6824.	12.4	11
8	Identification of novel salivary candidate protein biomarkers for tuberculosis diagnosis: A preliminary biomarker discovery study. Tuberculosis, 2021, 130, 102118.	1.9	5
9	Serum and cerebrospinal fluid host proteins indicate stroke in children with tuberculous meningitis. PLoS ONE, 2021, 16, e0250944.	2.5	4
10	OC 8435â€MULTI-BIOMARKER TEST STRIP FOR POINT-OF-CARE SCREENING FOR ACTIVE TUBERCULOSIS: A FIVE-COUNTRY MULTI-CENTRE TEST EVALUATION. BMJ Global Health, 2019, 4, A6.2-A6.	4.7	3